AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32557665
Drug: Intravenous garetosmab
RxNorm normalized name: Garetosmab
DrugBank: Garetosmab (DB16379)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous garetosmab 0.3, 1, 3, or 10 mg/kg
Trial: 32557665
Drug: Intravenous garetosmab
RxNorm normalized name: Garetosmab
DrugBank: Garetosmab (DB16379)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous garetosmab 10 mg/kg
Trial: 36163755
Drug: Quizartinib (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quizartinib (40 mg/day from days 8-21, followed by 30-60 mg/day for up to 3 years)
Trial: 34336162
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group using original images for diagnosis and treatment.
Trial: 34373901
Drug: Postoperative analgesic
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative analgesic effect after electrode insertion
Trial: 33676783
Drug: 9vHPV vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9vHPV vaccine (three-dose regimen: day 1, month 2, month 6)
Trial: 32954673
Drug: Biological movements
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological movements
Trial: 34134711
Drug: Low serum
RxNorm normalized name: ZINC OXIDE 20 g in 100 mL TOPICAL CREAM [Sunceutical SPF 50 Mineral Glow Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low serum urate (100 µmol/L)
Trial: 34134711
Drug: Median serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Median serum urate (300 µmol/L)
Trial: 32353974
Drug: Gymnema sylvestre
RxNorm normalized name: GYMNEMA SYLVESTRE LEAF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gymnema sylvestre (GS) solution
Trial: 33611742
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate 50 mg/kg intravenously, followed by infusion at a rate of 10 mg/kg/h during surgery
Trial: 32871238
Drug: Calcifediol treatment
RxNorm normalized name: Calcifediol
DrugBank: Calcifediol (DB00146)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcifediol treatment (0.532 mg on admission, 0.266 mg on days 3 and 7, then weekly until discharge or ICU admission)
Trial: 32871238
Drug: Best available
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Best available therapy (hydroxychloroquine and azithromycin) without calcifediol
Trial: 39218235
Drug: Calcifediol treatment
RxNorm normalized name: Calcifediol
DrugBank: Calcifediol (DB00146)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcifediol treatment
Trial: 32871238
Drug: Best available
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Best available therapy without calcifediol
Trial: 34211099
Drug: High-dose BTxA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose BTxA (8 U)
Trial: 34211099
Drug: Low-dose BTxA
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose BTxA (4 U)
Trial: 32880343
Drug: PZQ 40
RxNorm normalized name: L-PZQ
DrugBank: (R)-Praziquantel (DB11749)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PZQ 40 mg/kg
Trial: 32880343
Drug: PZQ 60
RxNorm normalized name: L-PZQ
DrugBank: (R)-Praziquantel (DB11749)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PZQ 60 mg/kg
Trial: 32171600
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of botulinum toxin A (BTX‐A) in the masticator muscles before surgery
Trial: 34569413
Drug: Lubricant gel
RxNorm normalized name: Surgilube Lubricant Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lubricant gel (5 ml of water-soluble lubricant gel during cervical dilatation of 4 cm until complete cervical dilatation)
Trial: 35986409
Drug: Oral glucose
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucose intake
Trial: 32473640
Drug: OM3-CA 2
RxNorm normalized name: Ca 2+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OM3-CA 2 g
Trial: 32473640
Drug: OM3-EE 4
RxNorm normalized name: norgestimate
DrugBank: Norgestimate (DB00957)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: OM3-EE 4 g
Trial: 33002427
Drug: Nebulised ALX‐0171
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulised ALX‐0171 3 mg/kg
Trial: 33002427
Drug: Nebulised ALX‐0171
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulised ALX‐0171 6 mg/kg
Trial: 33002427
Drug: Nebulised ALX‐0171
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulised ALX‐0171 9 mg/kg
Trial: 32221987
Drug: Brivaracetam at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brivaracetam at individualized doses ≤200 mg/d
Trial: 36432445
Drug: Concentrated beetroot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concentrated beetroot juice (140 mL)
Trial: 36432445
Drug: Low-nitrate control
RxNorm normalized name: Nitrate
DrugBank: Nitrate (DB14049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-nitrate control supplement
Trial: 34768404
Drug: Albumin (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albumin (1.5 g/kg at baseline and 1 g/kg on day 3)
Trial: 35303460
Drug: Community-based programme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community-based programme for corneal ulcer prevention involving training of female community health volunteers (FCHVs) to diagnose corneal abrasions and provide a 3-day course of ophthalmic antimicrobials.
Trial: 36041466
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of self-disclosure and high communication competence
Trial: 33306991
Drug: 2 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 μg ID93 + 5 μg GLA‐SE on days 0 and 56
Trial: 33306991
Drug: 2 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 μg ID93 + 5 μg GLA‐SE on days 0, 28, and 56
Trial: 35114131
Drug: High‐dose long‐acting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High‐dose long‐acting octreotide
Trial: 33831909
Drug: Switching to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switching to a single-tablet regimen of cobicistat, elvitregravir, emtricitabine along with tenofovir alafenamide
Trial: 33831909
Drug: Two-drug regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-drug regimen based on dolutegravir and one reverse transcriptase inhibitor (RTI)
Trial: 33378824
Drug: Quantitative fecal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quantitative fecal immunochemical test (FIT) at a cutoff value of 20 μg Hb/g
Trial: 33378824
Drug: Quantitative fecal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quantitative fecal immunochemical test (FIT) at a decreased cutoff value of 5 μg Hb/g
Trial: 36477547
Drug: No treatments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatments (control group)
Trial: 32270926
Drug: Fenebrutinib 50
RxNorm normalized name: Fenebrutinib
DrugBank: Fenebrutinib (DB14785)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenebrutinib 50 mg once daily
Trial: 32270926
Drug: Fenebrutinib 200
RxNorm normalized name: Fenebrutinib
DrugBank: Fenebrutinib (DB14785)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenebrutinib 200 mg twice daily (cohort 2)
Trial: 34793986
Drug: Supervised exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised exercise therapy (SET) plus OMT
Trial: 36329596
Drug: Esmolamine (0.1mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolamine (0.1mg/kg intravenous injection 10 min before induction, followed by 2 μg•kg‐1•min‐1 infusion)
Trial: 36329596
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline infusion (control group)
Trial: 34538227
Drug: five-flash intense
RxNorm normalized name: T8 Keto Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: five-flash intense pulsed light therapy (IPL)
Trial: 34549388
Drug: Single intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous doses of S-oxiracetam (S-ORT) at 2.0 g, 4.0 g, and 8.0 g
Trial: 34549388
Drug: Single intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous infusion of 3.0 g S-ORT
Trial: 34549388
Drug: Single intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous infusion of 6.0 g racemic oxiracetam (R-ORT)
Trial: 34549388
Drug: Daily intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily intravenous injection of 4.0 g S-ORT for 7 days
Trial: 34810345
Drug: Probiotic formulation
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic formulation applied for 6 consecutive days
Trial: 36228640
Drug: Daily contact
RxNorm normalized name: CONTACT LENS DAILY CLEANER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily contact testing (DCT) with seven lateral flow device (LFD) tests and two PCR tests, no isolation if negative on LFD.
Trial: 35417909
Drug: Once-weekly somatrogon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly somatrogon (0.25, 0.48, and 0.66 mg/kg/week for 12 months)
Trial: 35417909
Drug: Once-daily Genotropin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily Genotropin (0.025 mg/kg/day for 12 months)
Trial: 33588138
Drug: Dexamethasone (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (0.4 ml/mg)
Trial: 33588138
Drug: Long-acting betamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting betamethasone (0.1 ml/mg)
Trial: 36330832
Drug: Integrative adapt
RxNorm normalized name: ADAPT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrative adapt therapy (IAT)
Trial: 33030089
Drug: Propranolol 60
RxNorm normalized name: propranolol 60 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 60 mg twice daily
Trial: 32310040
Drug: Non-vitamin K
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-vitamin K antagonist oral anticoagulants
Trial: 32310040
Drug: Dual-drug approach
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual-drug approach with LMWH-VKA
Trial: 36286945
Drug: Aterixen (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aterixen (100 mg tablets)
Trial: 34025069
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (wait-and-see approach)
Trial: 33440985
Drug: Auricular acupressure
RxNorm normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Auricular acupressure (AA) applied on four points: shemen, liver, spleen, and finger/toe, thrice daily for 3 weeks
Trial: 33440985
Drug: Sham auricular
RxNorm normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham auricular acupressure applied on four remote points unrelated to neuropathic symptoms, thrice daily for 3 weeks
Trial: 34107141
Drug: Spirulina supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spirulina supplementation (1 g/day, two 500 mg capsules)
Trial: 32579807
Drug: 320 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 320 μg budesonide, 18 μg glycopyrrolate, 9.6 μg formoterol (triple therapy)
Trial: 32579807
Drug: 160 μg
RxNorm normalized name: immunoglobulin G, human 160 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160 μg budesonide, 18 μg glycopyrrolate, 9.6 μg formoterol (triple therapy)
Trial: 32579807
Drug: 18 μg
RxNorm normalized name: ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 18 μg glycopyrrolate, 9.6 μg formoterol (dual therapy)
Trial: 32579807
Drug: 320 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 320 μg budesonide, 9.6 μg formoterol (dual therapy)
Trial: 32437937
Drug: Antibiotic prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic prescription
Trial: 32945066
Drug: 30-g fecal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30-g fecal microbiota transplantation (FMT)
Trial: 32945066
Drug: 60-g fecal
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60-g fecal microbiota transplantation (FMT)
Trial: 35986239
Drug: Individualized treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized treatment strategy based on preoperative risk score
Trial: 35986239
Drug: Individualized treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized treatment strategy
Trial: 35333352
Drug: Intensive breast
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive breast milk nutritional support program (IBNSP) with breastfeeding, administered for the first 48 hours after birth, including face-to-face training and practical support.
Trial: 32149773
Drug: Methylprednisolone via
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone via intravenous injection at a dose of 1-2 mg/kg/day for 3 days
Trial: 36003030
Drug: Instrumental reminiscence
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Instrumental reminiscence therapy based on Roy's adaptation model
Trial: 33092707
Drug: TMVr with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMVr with the MitraClip plus guideline-directed medical therapy (GDMT)
Trial: 34481803
Drug: Nedosiran (1.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nedosiran (1.5, 3.0, or 6.0 mg/kg)
Trial: 34481803
Drug: Nedosiran (0.3,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nedosiran (0.3, 1.5, 3.0, 6.0, then 12.0 mg/kg)
Trial: 34362453
Drug: Intrathecal injection
RxNorm normalized name: BACLOFEN 50 ug in 1 mL INTRATHECAL INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal injection of umbilical cord tissue mesenchymal stem cells (UCT‐MSC), single-dose (2 × 10^7) cells.
Trial: 34768600
Drug: Dexamethasone (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (0.8 mg) and Bupivacaine (5%) with articaine–epinephrine (40/0.005 mg/mL)
Trial: 34768600
Drug: Articaine–epinephrine (40/0.005
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Articaine–epinephrine (40/0.005 mg/mL)
Trial: 34481524
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g tranexamic acid (TXA) administered immediately after induction of general anesthesia
Trial: 32305787
Drug: Very-low-dose spinal
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very-low-dose spinal analgesia (levobupivacaine 3.75 mg; sufentanil 2.5 μg)
Trial: 32305787
Drug: Low-dose spinal
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose spinal analgesia (levobupivacaine 7.5 mg; sufentanil 2.5 μg)
Trial: 32305787
Drug: Very-low-dose spinal
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very-low-dose spinal analgesia
Trial: 32305787
Drug: Low-dose spinal
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose spinal analgesia
Trial: 34481517
Drug: Secukinumab 150
RxNorm normalized name: secukinumab 150 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secukinumab 150 mg (with loading dose)
Trial: 34481517
Drug: Secukinumab 150
RxNorm normalized name: secukinumab 150 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secukinumab 150 mg (without loading dose)
Trial: 32446674
Drug: Established Status
RxNorm normalized name: Statuss Green Reformulated Jan 2012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Established Status Epilepticus Treatment Trial
Trial: 35206521
Drug: Peer-delivered stop-smoking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peer-delivered stop-smoking programme (group support, combination nicotine replacement therapy (NRT), and tailored individual support)
Trial: 32071149
Drug: Quercetin at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quercetin at 500, 1000 or 2000 mg/day for 1 week
Trial: 32233245
Drug: Intra-articular injection
RxNorm normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injection of PRP (2 ml) and extra-articular injection of PRP (2 ml), once a week for three times.
Trial: 32233245
Drug: Intra-articular injection
RxNorm normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injection of sodium hyaluronate (20 mg) and extra-articular injection of analgesic drug (2 ml for one point), once a week for three times.
Trial: 33387398
Drug: Silicone gel
RxNorm normalized name: SILTREX Silicone Gel-Pad
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silicone gel containing onion extract and aloe vera (SGOA)
Trial: 33387398
Drug: Silicone gel
RxNorm normalized name: SILTREX Silicone Gel-Pad
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silicone gel sheets (SGS)
Trial: 35697424
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care followed by delayed treatment with TranS‐C (UC‐DT)
Trial: 33877323
Drug: Liquid micellar
RxNorm normalized name: Douxo Micellar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid micellar preparation (1000 mg)
Trial: 33877323
Drug: Dried colloidal
RxNorm normalized name: peptone,dried
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dried colloidal suspension (300 mg)
Trial: 33877323
Drug: Standard turmeric
RxNorm normalized name: Turmeric
DrugBank: Turmeric (DB14276)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard turmeric extract (1500 mg)
Trial: 33877323
Drug: Piperine-curcuminoid combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperine-curcuminoid combination (1515 mg)
Trial: 33877323
Drug: Phytosome formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phytosome formulation (1000 mg)
Trial: 34782419
Drug: IV thrombolysis
RxNorm normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV thrombolysis with alteplase at 0.9 mg/kg body weight
Trial: 34106300
Drug: Sotagliflozin (SGLT2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sotagliflozin (SGLT2 inhibitor)
Trial: 34106300
Drug: Finerenon (mineralocorticoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finerenon (mineralocorticoid receptor antagonist)
Trial: 34106300
Drug: Kidney replacement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kidney replacement therapy initiation timing
Trial: 33727902
Drug: Basic activities
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic activities of daily living
Trial: 35140309
Drug: Oropharyngeal mother's
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oropharyngeal mother's milk administration for 14 days
Trial: 35140309
Drug: Oropharyngeal 0.9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oropharyngeal 0.9% normal saline administration
Trial: 32488680
Drug: CePROP =
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CePROP = 3.6 μg⋅ml−1 and CeREMI = 4 ng⋅ml−1
Trial: 35751549
Drug: Dry cupping
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dry cupping therapy (DCT) for 8 minutes daily for 15 days (Group A)
Trial: 35751549
Drug: Dry cupping
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dry cupping therapy (DCT) for 10 minutes daily for 15 days (Group B)
Trial: 35751549
Drug: Dry cupping
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dry cupping therapy (DCT) for 12 minutes daily for 15 days (Group C)
Trial: 33445205
Drug: GPB 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GPB 1% cream
Trial: 32125555
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy supplemented with 750 mg of S. boulardii CNCM I-745 daily for 2 weeks
Trial: 34390556
Drug: 8 weekly
RxNorm normalized name: Weekly Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 weekly stress management sessions
Trial: 33119680
Drug: Prescribed medications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescribed medications during the previous year
Trial: 33119680
Drug: Locally acting
RxNorm normalized name: Corticosteroids acting locally
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Locally acting antacids
Trial: 33119680
Drug: Loop diuretics
RxNorm normalized name: LOOP DIURETICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loop diuretics (e.g., furosemide)
Trial: 33119680
Drug: Major cardiovascular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Major cardiovascular drug classes
Trial: 32639688
Drug: Cluster needling
RxNorm normalized name: cluster fig extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cluster needling of scalp acupuncture on top of drug treatment
Trial: 35466438
Drug: Acalabrutinib suspension
DrugBank: Acalabrutinib (DB11703)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Acalabrutinib suspension (Acala-NG) administered via NG tube
Trial: 35466438
Drug: Acalabrutinib suspension
DrugBank: Acalabrutinib (DB11703)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Acalabrutinib suspension (Acala-NG) with PPI (rabeprazole)
Trial: 35466438
Drug: Oral acalabrutinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral acalabrutinib capsule administered with water
Trial: 35178208
Drug: Melatonin (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (6 mg BD for 3 days)